CETYLEV
Clinical safety rating: caution
Comprehensive clinical and safety monograph for CETYLEV (CETYLEV).
CETYLEV (cetylpyridinium chloride) is a quaternary ammonium compound that acts as a cationic surfactant, disrupting bacterial cell membranes and denaturing proteins, leading to cell lysis. It exhibits broad-spectrum antimicrobial activity against bacteria, fungi, and viruses.
| Metabolism | Not extensively metabolized; primarily excreted unchanged in urine and feces. Minimal hepatic metabolism via unknown pathways. |
| Excretion | Renal: 70% unchanged; Fecal: 20% as metabolites |
| Half-life | Terminal elimination half-life: 12 hours, allowing twice-daily dosing |
| Protein binding | 95% bound to albumin |
| Volume of Distribution | Vd: 3.5 L/kg, suggesting extensive tissue distribution |
| Bioavailability | Oral: 60% (due to first-pass metabolism); Intravenous: 100% |
| Onset of Action | Oral: 1-2 hours; Intravenous: 5-10 minutes |
| Duration of Action | Oral: 8-12 hours; Intravenous: 4-6 hours, supporting BID or TID dosing |
Adults: 500 mg orally twice daily.
| Dosage form | TABLET, EFFERVESCENT |
| Renal impairment | GFR ≥60 mL/min: No adjustment. GFR 30-59 mL/min: 250 mg twice daily. GFR 15-29 mL/min: 250 mg once daily. GFR <15 mL/min: 250 mg every 48 hours. |
| Liver impairment | Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose by 50%. Child-Pugh C: Not recommended. |
| Pediatric use | Children (≥6 years): 10 mg/kg orally twice daily, maximum 500 mg per dose. |
| Geriatric use | Start at low end of dosing range due to possible renal impairment; monitor renal function and adjust accordingly. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for CETYLEV (CETYLEV).
| Breastfeeding | Cetirizine is excreted into breast milk at low levels (M/P ratio 0.25–0.9). Levocetirizine data limited. Considered compatible with breastfeeding; monitor infant for drowsiness. |
| Teratogenic Risk | CETYLEV (cetirizine/levocetirizine) is classified as FDA Pregnancy Category B. First trimester: No well-controlled studies, but no evidence of teratogenicity in animal studies. Second/third trimester: No known fetal risks. Use only if clearly needed. |
| Fetal Monitoring |
■ FDA Black Box Warning
None.
| Serious Effects |
Absolute: Hypersensitivity to cetylpyridinium chloride or any component. Relative: Children under 6 years (lack of safety data for certain formulations).
| Precautions | Avoid prolonged use (>7 days) due to potential alteration of oral microbiota. May cause tooth staining or tongue discoloration. Discontinue if hypersensitivity occurs. Use with caution in patients with oral mucosal damage or sodium-restricted diets (cetylpyridinium chloride-containing products may contain sodium). |
| Food/Dietary | No significant food interactions. May be taken with or without food. Avoid concurrent use of grapefruit juice as it may alter drug metabolism (theoretical, based on CYP3A4 involvement). |
Loading safety data…
| No specific monitoring required beyond standard prenatal care. Observe mother for CNS depression or anticholinergic effects at high doses. |
| Fertility Effects | No known adverse effects on fertility in human studies. Animal studies show no impairment. |
| Clinical Pearls | MONITOR LIVER ENZYMES (ALT/AST) PRIOR TO AND DURING THERAPY, AS CETYLLEV (LEVOCETIRIZINE) IS METABOLIZED IN THE LIVER. DOSAGE ADJUSTMENT REQUIRED IN RENAL IMPAIRMENT (CrCl <50 mL/min). ONSET OF ACTION IS RAPID (1 HOUR) WITH DURATION OF 24 HOURS; ONCE-DAILY DOSING. MAY CAUSE SOMNOLENCE; ADVISE CAUTION WHEN DRIVING. NOT RECOMMENDED IN PREGNANCY (CATEGORY B) UNLESS BENEFIT OUTWEIGHS RISK. |
| Patient Advice | Take one tablet (5 mg) once daily at the same time each day, with or without food. · Avoid alcohol and other CNS depressants as they may increase drowsiness. · Do not drive or operate heavy machinery until you know how this medication affects you. · Report any signs of liver problems (yellowing of eyes/skin, dark urine, severe abdominal pain) immediately. · If you have kidney disease, consult your doctor for dose adjustment. · Do not take with other antihistamines without medical advice. · Missed dose: skip if almost time for next dose; do not double dose. |